Propofol (2,6-Diisopropylphenol)

Structure & Formulation

Propofol chemical structure — alkylphenol derivative

Propofol is an alkylphenol — specifically 2,6-diisopropylphenol. It is highly lipid-soluble and insoluble in water, necessitating an emulsion formulation:

1% propofol + 10% soybean oil + 1.2% purified egg phospholipid (emulsifier) + 2.25% glycerol (tonicity) + sodium hydroxide (pH adjustment) + EDTA (bacteriostatic)
Appears as a milky-white viscous emulsion; pH 7
Stable at room temperature, not light-sensitive; may be diluted with 5% dextrose

Fospropofol (Lusedra): A water-soluble prodrug approved by FDA in 2008 for monitored anesthesia care. Metabolized by alkaline phosphatases to propofol. Avoids injection pain but causes perineal paresthesias and pruritus after bolus dosing.

Mechanism of Action

Propofol's primary mechanism is enhancement of GABA-mediated inhibitory neurotransmission at GABA-A receptors — increasing chloride conductance and hyperpolarizing the neuronal membrane. This leads to CNS depression ranging from sedation to general anesthesia in a dose-dependent manner. Additional actions include inhibition of NMDA receptor activity and modulation of glycine receptors.

Pharmacokinetics

Plasma concentration after propofol 2 mg/kg induction dose

After an induction bolus, plasma levels fall rapidly due to redistribution; levels required for surgical anesthesia are 2–5 mcg/mL, with awakening typically occurring below 1.5 mcg/mL.

Parameter	Value
Initial distribution t½	2–8 min
Slow distribution t½	30–70 min
Elimination t½	4–23.5 hours
Context-sensitive half-time (≤8h infusion)	< 40 min
Volume of distribution (central compartment)	6–40 L
Volume of distribution (steady state)	150–700 L
Clearance	1.5–2.2 L/min (exceeds hepatic blood flow)

Metabolism: Oxidized in the liver to 1,4-diisopropyl-1,4-quinol (glucuronide conjugate excreted in urine). Extrahepatic metabolism also occurs (~30% first-pass pulmonary uptake). Less than 1% is excreted unchanged. After a 2.5-hour anesthetic, propofol metabolites appear in urine for >60 hours.

Drug interactions: Propofol is a CYP3A4 inhibitor — at blood concentrations of 3 mcg/mL, CYP3A4 activity is reduced ~37%. Midazolam elevates propofol blood levels by ~25% due to competition at this enzyme.

Elderly patients: Reduced cardiac output → smaller central compartment → higher peak plasma concentration; doses should be reduced.

Clinical Uses & Dosing

Indication	Dose
IV induction (adults)	1.5–2.5 mg/kg IV
IV induction (elderly/compromised)	1–1.5 mg/kg IV (reduced)
Maintenance of anesthesia	100–150 mcg/kg/min infusion
ICU/procedural sedation	25–75 mcg/kg/min infusion
Target blood concentration for surgery	2–5 mcg/mL

Target-controlled infusion (TCI) systems (e.g., Marsh, Schnider models) are widely used to achieve precise pharmacokinetic targets. A 2025 systematic review (PMID 40289063) confirms that TCI propofol remains highly effective for individualized anesthesia.

Organ System Effects

Central Nervous System

Decreases cerebral blood flow (CBF) by 53–79% and cerebral metabolic rate (CMR) by 48–58% (PET data in volunteers)
Reduces ICP and CSF pressure
CO₂ reactivity and cerebral autoregulation are preserved, even at burst-suppression doses
Does not have analgesic properties
Antiemetic at sub-anesthetic doses (a major clinical advantage)
EEG: Produces dose-dependent slowing → burst suppression at high doses

⚠️ In patients with elevated ICP, propofol can cause a critical reduction in CPP (<50 mmHg) unless mean arterial pressure is supported.

Cardiovascular System

Hypotension — the most clinically significant adverse effect; results from vasodilation (decreased SVR) and a modest decrease in myocardial contractility
Decreases myocardial blood flow and oxygen consumption — global O₂ supply-to-demand ratio is likely preserved
Heart rate is generally unchanged or mildly reduced
Baroreflex responses are attenuated

Respiratory System

Dose-dependent respiratory depression — apnea is common after induction bolus
Reduces tidal volume and respiratory rate
Bronchodilator in patients with reactive airway disease (effect depends on the preservative; the metabisulfite-containing formulation may be less effective)
Suppresses upper airway reflexes (facilitates LMA placement)

Other Effects

No neuromuscular blockade — does not affect the twitch or EMG; however, acceptable intubating conditions have been reported with propofol alone
Does NOT trigger malignant hyperthermia — safe in susceptible patients
Anticonvulsant properties (also used in refractory status epilepticus)
Mild antipruritic effects

Adverse Effects & Contraindications

Effect	Details
Pain on injection	Very common (~70%); reduced by prior IV lidocaine, administering into a large vein, or using lipid-modified formulations
Propofol infusion syndrome (PRIS)	Rare but potentially fatal; associated with high-dose, prolonged infusions (>4 mg/kg/h for >48h) — metabolic acidosis, rhabdomyolysis, cardiac failure, lipemic plasma. Most often in critically ill children and adults on ICU sedation
Hypotension	Especially at induction; exaggerated in hypovolemic, elderly, or cardiac patients
Apnea	Occurs in most patients after induction bolus
Hypertriglyceridemia	With prolonged infusions due to lipid vehicle
Allergy	True anaphylaxis is rare; egg/soy allergy does not reliably predict propofol allergy (purified phospholipid fraction used)
Fetal neurotoxicity	FDA (December 2016) warning: concern about prolonged/repetitive exposure to general anesthetics including propofol affecting fetal brain development (based on animal studies)
Green discoloration of urine	Benign; due to phenolic metabolites

Special Populations

Pediatric patients: Higher induction dose required (2.5–3 mg/kg); PRIS risk is higher in critically ill children — avoid prolonged high-dose ICU sedation. FDA neurotoxicity warning applies to repeated/prolonged exposures in children <3 years
Elderly: Reduced dose required; increased sensitivity and hemodynamic depression
Pregnancy: Used for cesarean section induction; crosses placenta; neonates metabolize propofol; causes variability in neonatal elimination
Liver/renal disease: Clearance modestly affected; extrahepatic metabolism provides some protection

Propofol vs. Newer Agents

Recent comparative evidence:

Ciprofol vs. Propofol (2024 meta-analysis, PMID 38412619): Ciprofol shows comparable efficacy for induction with potentially better hemodynamic stability and less injection pain
Remimazolam vs. Propofol in elderly (2024 meta-analysis, PMID 39069837): Remimazolam associated with less hypotension and respiratory depression in elderly patients; propofol still remains standard

Key Clinical Points Summary

Most commonly used IV hypnotic worldwide for induction and maintenance of anesthesia and procedural sedation
Rapid onset (30–60 sec) and rapid recovery (context-sensitive half-time <40 min even after 8-hour infusion) — ideal for ambulatory and day-case surgery
Antiemetic properties distinguish it from other agents
No analgesic effect — must combine with opioids or regional techniques
Avoid in suspected PRIS — monitor triglycerides and urine in prolonged ICU use
Hemodynamic vigilance required — especially in elderly, hypovolemic, or cardiac patients

— Miller's Anesthesia, 10th ed.

This is a shared conversation. Sign in to Orris to start your own chat.